78 related articles for article (PubMed ID: 23756372)
1. How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001-2012.
Ward DJ; Slade A; Genus T; Martino OI; Stevens AJ
BMJ Open; 2014 Oct; 4(10):e006235. PubMed ID: 25344485
[TBL] [Abstract][Full Text] [Related]
2. Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s.
Okuyama R
Drug Discov Today; 2024 Feb; 29(2):103866. PubMed ID: 38145871
[TBL] [Abstract][Full Text] [Related]
3. Refining the impact of genetic evidence on clinical success.
Minikel EV; Painter JL; Dong CC; Nelson MR
Nature; 2024 May; 629(8012):624-629. PubMed ID: 38632401
[TBL] [Abstract][Full Text] [Related]
4. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication.
Rask-Andersen M; Masuram S; Schiöth HB
Annu Rev Pharmacol Toxicol; 2014; 54():9-26. PubMed ID: 24016212
[TBL] [Abstract][Full Text] [Related]
5. Novelty in the target landscape of the pharmaceutical industry.
Agarwal P; Sanseau P; Cardon LR
Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
[No Abstract] [Full Text] [Related]
6. The discovery of first-in-class drugs: origins and evolution.
Eder J; Sedrani R; Wiesmann C
Nat Rev Drug Discov; 2014 Aug; 13(8):577-87. PubMed ID: 25033734
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive map of molecular drug targets.
Santos R; Ursu O; Gaulton A; Bento AP; Donadi RS; Bologa CG; Karlsson A; Al-Lazikani B; Hersey A; Oprea TI; Overington JP
Nat Rev Drug Discov; 2017 Jan; 16(1):19-34. PubMed ID: 27910877
[TBL] [Abstract][Full Text] [Related]
8. A Drug-Centric View of Drug Development: How Drugs Spread from Disease to Disease.
Rodriguez-Esteban R
PLoS Comput Biol; 2016 Apr; 12(4):e1004852. PubMed ID: 27124390
[TBL] [Abstract][Full Text] [Related]
9. Composition and applications of focus libraries to phenotypic assays.
Wassermann AM; Camargo LM; Auld DS
Front Pharmacol; 2014; 5():164. PubMed ID: 25104937
[TBL] [Abstract][Full Text] [Related]
10. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
11. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
Kaitin KI; DiMasi JA
Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
[TBL] [Abstract][Full Text] [Related]
12. 2018 in review: FDA approvals of new molecular entities.
Kinch MS; Griesenauer RH
Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
[TBL] [Abstract][Full Text] [Related]
13. A forensic analysis of drug targets from 2000 through 2012.
Munos B
Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
[TBL] [Abstract][Full Text] [Related]
14. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
15. Reinventing bioinnovation.
Kaitin KI; Honig PK
Clin Pharmacol Ther; 2013 Sep; 94(3):279-83. PubMed ID: 23963211
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
